Monash IVF Group Limited re-confirms profit guidance provided in November 2019. The company anticipates fiscal 2020 NPAT before non-regular items for the year ended 30 June 2020 will be in the range of $18.0 million to $19.0 million. Non-regular items are expected to include transaction costs associated with acquisition activity, restructuring costs applicable to the cost reduction program, pre-IPO disputed patient claim and start-up costs associated with opening of the new Sydney CBD fertility clinic expected in the fourth quarter of fiscal 2020. The Group remains well positioned to optimise future earnings through strategic and operational momentum gained during the 2019 calendar year.